An Updated Meta-analysis on the Risk of Urologic Cancer in Patients with Systemic Lupus Erythematosus by 심재용
Arch Iran Med. September 2020;23(9):614-620
Systematic Review
An Updated Meta-analysis on the Risk of Urologic 
Cancer in Patients with Systemic Lupus Erythematosus
Jina Yeo, MD1#; Min-Seok Seo, MD2,3#; In Cheol Hwang, PhD4*; Jae-Yong Shim, PhD3
1Rheumatology Division, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea
2Department of Family Medicine, Incheon St. Mary’s Hospital, Incheon, Republic of Korea
3Yonsei University Graduate School of Medicine, Seoul, Republic of Korea
4Department of Family Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea 
Received: July 29, 2019, Accepted: April 22, 2020, ePublished: September 1, 2020
Abstract
Background: The risk of urologic cancers in patients with systemic lupus erythematosus (SLE) remains uncertain. We investigated 
the association between SLE and incident urologic cancers through a systematic review and meta-analysis.
Methods: We searched the PubMed, EMBASE, and the Cochrane Library to identify articles that recorded prostate, bladder, or 
kidney cancers in SLE patients from inception to August 31, 2018. We included observational, case-control, or cohort studies with 
no language restriction. Two investigators screened and extracted the data independently.
Results: Fourteen cohort studies with 83,860 SLE patients were finally analyzed. Overall, SLE patients were at increased risk of 
bladder cancer (hazard ratio [HR], 1.92; 95% confidence interval [CI], 1.15–3.21) but not of prostate or kidney cancer. However, 
subgroup analyses showed a reduced risk of prostate cancer in <10-year follow-up studies (HR, 0.68; 95% CI, 0.51–0.89) and an 
elevated risk of kidney cancer in patients with SLE in Western studies (HR, 2.00; 95% CI, 1.02–3.92), community-based studies 
(HR, 4.54; 95% CI, 2.17–9.52), prospective studies (HR, 6.84; 95% CI, 2.71–17.26), <10-year follow-up studies (HR, 1.88; 95% 
CI, 1.38–2.57), and low-quality studies (HR, 2.05; 95% CI, 1.50–2.80). 
Conclusion: This study indicates that SLE increases the risk of bladder cancer but not prostate or kidney cancer. Well-designed 
long-term studies are required to confirm these associations. 
Keywords: Bladder cancer, Kidney cancer, Meta-analysis, Prostate cancer, Systemic lupus erythematosus 
Cite this article as: Yeo J, Seo MS, Hwang IC, Shim JY. An updated meta-analysis on the risk of urologic cancer in patients with 
systemic lupus erythematosus. Arch Iran Med. 2020;23(9):614–620. doi: 10.34172/aim.2020.72.
#Contributed equally to the work as first authors.
*Corresponding Author: In Cheol Hwang, PhD; Gil Medical Center, Gachon University College of Medicine, 1198 Guwol-dong, Namdong-gu, Incheon 405-760, 






Systemic lupus erythematosus (SLE) affects virtually 
every organ and causes diverse clinical manifestations 
and laboratory findings.1 SLE is usually treated with 
systemic steroids and/or immune suppressants.2 Recently, 
biologic agents have been used to increase the survival 
rate of SLE patients.3 However, associated conditions 
(e.g., dyslipidemia, diabetes mellitus, and osteoporosis), 
and particularly malignancies, still play a crucial role in 
the long-term outcomes of SLE patients.4 Several studies 
have indicated that SLE patients are at increased risk for 
malignant tumors caused by a decline of the intrinsic 
immune system and exposure to cytotoxic agents.5,6 The 
association between SLE and malignant tumors is still not 
fully understood, and cancer surveillance for patients with 
SLE is the same as that for the general population.7
Urologic cancers are relatively common. Prostate cancer 
remains the second most frequent cancer and the fifth 
leading cause of male cancer death, accounting for 7.1% 
of all new cases of cancer and 3.8% of all cancer deaths 
worldwide in 2018. Bladder cancer ranks as the tenth most 
common cancer, with approximately 549 000 new cases 
and 200 000 deaths worldwide in 2018.8 Kidney cancer 
accounted for nearly 403 000 new cases and 175 000 
deaths in 2018. 
Cammarata et al reported an association between SLE 
and lymphoma in 1963.9 Since then, the relationship 
between SLE and malignancies, including urologic cancers, 
has been studied. According to previous researches, some 
potential mechanisms in the development of urologic 
cancers, especially prostate cancer, are related to hormonal 
effects and cytokine pathways.10,11
Until now, several meta-analyses have shown 
inconclusive results concerning incident urologic cancers 
in SLE patients.12-15 A decreased risk of prostate cancer 
was shown in Huang’s study, while Cao et al and Mao et 
al failed to show a decrease.12-14 With respect to bladder 
cancer, only Cao et al  demonstrated that SLE patients 
were at increased risk of bladder cancer.12 Additionally, 
Huang et al. and Mao et al. found higher risk of kidney 
cancer among SLE patients,13,14 while Cao et al found that 
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Song et al reported lower risk of prostate cancer and higher 
risk of bladder and kidney cancer in SLE patients,15 but 
their study has a critical problem with duplicate data. 
Therefore, to elucidate the association between SLE and 
urologic malignancy, we conducted a meta-analysis using 
published studies without duplicate data.
Materials and Methods
Data Sources and Literature Search
A systematic review and meta-analysis were performed to 
evaluate incident urologic cancer among SLE patients. 
We followed the guideline of Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) 
statement.16 For this systematic review, we identified 
studies reporting the incidence of urologic cancers in SLE 
patients. Two investigators (J.Y. and M.S.S) independently 
searched the PubMed, EMBASE, and the Cochrane 
Library databases for articles published from inception 
to August 31, 2018 that reported on the relationships 
between SLE and urologic cancers. The bibliography of 
the included papers was searched manually for additional 
studies. We used the following search terms: cancer, 
carcinoma, neoplasm, malignancy, malignancies, tumor, or 
tumour with systemic lupus erythematosus, autoimmune 
disease, rheumatic disease, or SLE. No limits were applied 
for language.
Eligibility Criteria and Study Selection
Eligible studies fulfilled the following inclusion criteria: 
1) observational, case-control, or cohort study; 2) SLE 
as one of exposures; 3) urologic cancer (prostate, bladder, 
or kidney) as one of outcomes; 4) general population as 
control; and 5) providing standardized incidence rate, 
hazard ratio (HR), relative risk, or odds ratio and the 
corresponding 95% confidence intervals (CIs). The 
exclusion criteria were: 1) reviews, editorials, letters, case 
reports or expert opinions; or 2) duplicated publications 
or overlapping study populations. Two investigators 
independently identified articles that met the eligibility 
criteria through screening all titles and abstracts, followed 
by reviews of full-text. When there were duplicates from 
the same database or overlapping populations, we chose the 
most appropriate study for inclusion in our analysis. Any 
inconsistency in opinions between the two investigators 
was resolved by an independent investigator (I.C.H).
Data Collection and Quality Assessment
Two investigators (J.Y. and M.S.S) collected the relevant 
data independently. The extracted data included: first 
author, year published, country, data source, gender, 
design type, follow-up periods, observed/estimated 
number, estimates and 95% CIs, and adjusted covariates. 
We used a Newcastle-Ottawa Scale (NOS) to assess the 
methodological quality of study.17 Based on the median 
values in our analysis, high quality studies were defined as 
those with an NOS score of 7 or more. Any disagreements 
between two investigators were solved through discussion 
and consensus with all authors.
Statistical Analysis
Urologic cancer risk was evaluated using pooled HRs with 
95% CIs, which were calculated cumulatively across the 
selected publication. We also performed subgroup analyses 
by ethnicity, study design, data source, follow-up period, 
and study quality. In contrast to the other two cancers, 
prostate cancer was analyzed only for male subjects. 
Between-study heterogeneity was estimated by Higgins 
I2 (0–100%).18 When heterogeneity was substantial (I2 
≥50%), a random (DerSimonian-Laird) effect model was 
applied.19 Furthermore, we performed a sensitivity analysis 
to reflect the impact of different decisions on outcomes by 
excluding specific study. We checked for publication bias 
using Begg’s rank correlation. We performed statistical 




A flowchart of the study identification procedure is shown 
in Figure 1. A total of 1,011 articles were initially screened 
through a systematic search. We excluded duplicate 
publications (n = 430) and papers that appeared irrelevant 
based on the title (n = 447). After screening the abstracts, 
we excluded 117 studies due to the following reasons: not 
original articles (n = 36), not focusing on cancer risk (n = 
23), and not including urologic cancers (n = 58). We then 
conducted a full-text review of 17 articles that fulfilled 
our eligibility criteria. Six papers were further excluded 
because of overlapping populations and three papers were 
added after conducting a manual literature search. Thus, 
Figure 1. Flow Chart for Searching Relevant Articles.
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14 articles were finally included in the analysis.
Detailed information about the studies are presented 
in Table 1. Our meta-analysis included a total of 83,860 
patients with SLE. The publication period was from 1996 
to 2018. Eight studies were conducted in Europe, two 
in Asia, and three in North America. There was also one 
multinational study from North America, Europe, and 
Korea. Eleven of the studies were retrospective, and three 
were prospective. Nine of the studies were hospital-based, 
while the other five were population-based. Supplementary 
Table 1 shows the methodological quality of studies. The 
mean NOS score among the 14 studies was 6.28. Six of 
the studies were classified as high quality. 
Urologic Cancers in SLE
There were 10 studies providing HRs for prostate cancers. 
The pooled HR for prostate cancer among patients with 
SLE was 0.92 (95% CI, 0.65–1.30; I2=74.7%; Figure 2), 
suggesting that SLE was not a significant risk factor for 
prostate cancer. However, subgroup analyses restricted by 
follow-up duration showed that patients with SLE had 
a reduced risk of prostate cancer in <10-year follow-up 
studies within the fixed-effects model (HR, 0.68; 95% CI, 
0.51–0.89; Table 2).
For bladder cancer, analysis of 10 studies revealed that 
the overall HR was 1.92 (95% CI, 1.15–3.21; I2 = 80.2%; 
Figure 2). Our results indicated that SLE was associated 
with higher risk of bladder cancer. Similarly, sensitivity 
analysis by excluding Kang’s study presented significant 
association (HR, 1.46; 95% CI, 1.01–2.11; I2 = 59.5%, 
random-effects model). In the subgroup analyses, the 
risk of bladder cancer was also higher in SLE patients 
in community-based studies (HR, 3.14; 95% CI, 1.05–
9.41), retrospective studies (HR, 1.97; 95% CI, 1.05–
3.70), and ≥10-year follow-up studies (HR, 2.38; 95% CI, 
1.76–3.23) (Table 2). 
Finally, kidney cancer was analyzed in eight studies. 
They failed to indicate a significant association between 
SLE and kidney cancer (HR, 1.72; 95% CI, 0.94–3.14; 
I2 = 62.7%; Figure 2). The regional subgroup analysis 
revealed that Western (North American and European) 
studies conferred a significantly higher risk of kidney 
cancer within the random-effects model (HR, 2.00; 95% 
CI, 1.02–3.92). When we stratified subgroup analysis 
by some characteristics, we found that the risk of kidney 
cancer was also higher in SLE patients among community-
based studies (HR, 4.54; 95% CI, 2.17–9.52), prospective 
studies (HR, 6.84; 95% CI, 2.71–17.26), <10-year follow-
up studies (HR, 1.88; 95% CI, 1.38–2.57), and low-
quality studies (HR, 2.05; 95% CI, 1.50–2.80) within the 
fixed-effects model.
There was no marked asymmetry in the funnel plot 
(Figure 3). No publication biases were noted from the 
Begg’s (P = 0.621) and Egger’s tests (P = 0.733).
Discussion
A number of studies have examined the association between 
SLE and cancers and found an increased overall cancer risk 
in patients with SLE.20-22 There is accumulating evidence 
that the risks of non-Hodgkin’s lymphoma, leukemia, 
cancer of the vulva, and lung cancer are increased in patients 
with SLE, whereas results have been inconsistent for some 
other solid cancers, including urologic cancers.23,24 Several 
meta-analyses have attempted to clarify the relationship 
between SLE and urologic cancers, but the results have 
been mixed.12-15 We identified a critical error in the data 
selection for the most recent meta-study by Song et al,15 
who included duplicate data from three studies.21,25-26 On 
Table 1. Characteristics of the Included Studies









Abu-Shakra53 1996 Canada Hospital Prospective 724/86.6 10 7
Mellemkjaer34 1997 Denmark Hospital Retrospective 1585/83 6.8 6
Cibere22 2001 Canada Hospital Retrospective 297/84 12 7
Ragnarsson54 2003 Iceland Nationwide Retrospective 238/89.5 12.8 7
Tarr55 2007 Hungary Hospital Retrospective 860/89.7 16.5 6
Parikh-Patel24 2008 USA Statewide Retrospective 30 478/89 5.1 Race 7
Kang32 2010 Korea Hospital Retrospective 914/100 6.2 6
Dreyer33 2011 Denmark Hospital Retrospective 576/88 13.2 5
Bernatsky23 2013 International Hospital Prospective 16 409/90 7.4 6
Dey27 2013 UK Hospital Retrospective 595/NR 14.7 6
Liu29 2013 Sweden Nationwide Retrospective 7624/NR 11.3 Obesity, region, alcohol, smoking 7
Rees30 2016 UK Nationwide Retrospective 7732/85.8 8.4
Alcohol, smoking, hypertension, 
BMI, Charlson index score, 
hyperlipidemia, Prednisolone
6
Yu28 2016 Taiwan Nationwide Retrospective 15 623/87.6 7.9 5
Tallbacka56 2018 Finland Hospital Prospective 205/88.78 25.7 7
BMI, body mass index; NR, not reported; SLE, systemic lupus erythematosus.
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the other hand, some studies used more updated data.23,27-
28 Another crucial problem with previous meta-analyses of 
SLE and urological cancer risk is that some of the meta-
analyses missed some principal studies. We included Liu’s 
study instead of Bjornadal’s study in our meta-analysis, 
because the former used more inclusive data.20,29 We also 
included Rees’s study.30 Complementing some of the 
limitations of Song’s meta-analysis,15 our study provides 
more specific estimates from unduplicated and recent data.
In this study, bladder cancer was more commonly 
developed in SLE patients compared with the general 
population. Previous meta-studies have shown inconsistent 
results.12-15 However, some researchers suggested that the 
high risk for bladder cancer in SLE patients might be due 
to lupus cystitis, viral infection, or SLE treatment such 
as cyclophosphamide.31-33 In addition, stratified analyses 
suggested several factors (i.e., data sources, study design 
and follow-up duration) as potential mediators for the 
relationships between SLE and bladder cancer. 
On the other hand, the association of SLE with prostate 
Figure 2. Forest Plot of Site-Specific Urologic Cancer Risk in SLE Patients. SLE, systemic lupus erythematosus; HR, hazard ratio; CI, confidence interval.
Table 2. Risk of Urologic Cancers in SLE Patients
Kidney Bladder Prostate
n HR (95% CI) Model n HR (95% CI) Model n HR (95% CI) Model
Overall 8 1.72 (0.94–3.14) Random 10 1.92 (1.15–3.21) Random 10 0.86 (0.70–1.05) Fixed
Ethnicity
Asian 2 0.75 (0.22–2.57) Fixed 3 4.03 (0.52–31.26) Random 2 0.55 (0.16–1.90) Fixed
Western 6 2.00 (1.02–3.92) Random 7 1.50 (0.96–2.35) Random 8 0.87 (0.71–1.07) Fixed
Data source
Nationwide 4 4.54 (2.17–9.52) Fixed 6 3.14 (1.05–9.41) Random 5 1.45 (0.50–4.23) Random
Hospital-based 4 1.19 (0.61–2.29) Random 4 1.25 (0.72–2.15) Random 5 0.82 (0.66–1.03) Fixed
Design
Prospective 2 6.84 (2.71–17.26) Fixed 2 1.37 (0.86–2.20) Fixed 2 0.64 (0.34–1.20) Fixed
Retrospective 6 1.32 (0.75–2.30) Random 8 1.97 (1.05–3.70) Random 8 0.89 (0.72–1.10) Fixed
Follow-up duration
≥10 years 4 2.67 (0.77–9.27) Random 4 2.38 (1.76–3.23) Fixed 6 1.17 (0.86–1.59) Fixed
<10 years 4 1.88 (1.38–2.57) Fixed 6 1.75 (0.85–3.56) Random 4 0.68 (0.51–0.89) Fixed
Study quality
High (NOS ≥7) 4 1.80 (0.49–6.54) Random 4 1.50 (0.82–2.76) Random 4 0.93 (0.70–1.25) Fixed
Low (NOS <7) 4 2.05 (1.50–2.80) Fixed 6 2.40 (0.89–6.49) Random 6 1.18 (0.52–2.70) Random
SLE, systemic lupus erythematosus; HR, hazard ratio; CI, confidence interval; NOS, Newcastle-Ottawa Scale.
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cancer remained insignificant. An early meta-analysis 
reported low risk of prostate cancer in SLE patients;13 but 
two subsequent meta-studies did not show a significant 
relationship between SLE and reduced risk of prostate 
cancer.12,14 Huang’s study was hampered by missing data, 
however, whereas Mao’s study contained duplicate data. 
To clarify that inconsistency, we used the most recent 
available data without duplicates. There are some clinical 
considerations that might shed some light on our result. 
First, SLE is a female-dominant disease,34 but prostate 
cancer only occurs in males, so there might be insufficient 
data to examine the incident prostate cancer among 
patients with SLE. Second, prostate cancer has peak 
incidence in males 65 years of age or older.35 Interestingly, 
our subgroup analysis presented a low risk of prostate 
cancer among studies with <10-year follow-up period. It 
may be attributed to hormonal effect, which is remarkable 
in patients at early stage of SLE, a relatively large proportion 
of whom have severe symptoms. Given the high disease 
activity of SLE correlated to hypoandrogenism,10,36 we 
assumed that patients at early stage SLE have high disease 
activity but low testosterone level, leading to lower risk for 
developing prostate cancer. 
For kidney cancer, we did not find an overall significant 
association, in contrast to two previous meta-studies.14,15 
In our subgroup analyses, however, the risk of kidney 
cancer was increased in Western SLE patients but not in 
Asian SLE patients. The difference in the risk of kidney 
cancer by ethnicity may be explained partly by genetic 
backgrounds which influence immunity and tumor 
genesis.37 It is well known that the incidence of kidney 
cancer in the general population is higher in Europe and 
North America compared to Asia.38 Considering the 
higher incidence of kidney cancer in Western populations, 
we suggest that Western SLE patients should be attentively 
monitored for the development of kidney cancer.
We found high risk for kidney cancer among nationwide 
studies but not in hospital-based studies. The nationwide 
data might have an advantage in that they included the 
Figure 3. Funnel Plot Using a Begg’s Rank Correlation among the Included 
Studies. HR, hazard ratio.
actual primary diagnosis, whereas the hospital-based data 
were secondary to the identification of cases. Despite 
efforts to minimize data errors, even the nationwide data 
may contain coding and keying errors. The use of hospital-
based data requires careful considerations to account 
for imperfect ascertainment of disease status,39 because 
hospital-based studies use administrative data and various 
algorithms to identify SLE, which may result in reduced 
quality of diagnoses. 
We found that SLE patients had a high risk for 
kidney cancer among studies with <10 years of follow-
up. That might be partly explained by the intensive use 
of immunosuppressive agents during the early stage of 
SLE.40 Most studies, including our meta-analysis, did not 
consider the use of immunosuppressants. The cumulative 
effects of immunosuppressants are another important 
consideration.41 Studies with long follow-up reflecting 
long-term use of immunosuppressive drugs are required 
to clarify our results. 
Although the relationship between SLE and urologic 
cancers remains unclear, there are some plausible 
hypotheses that might explain the elevated risk of 
urologic cancers in patients with SLE. First, the chronic 
inflammation in SLE can influence the development of 
urologic cancers. Chronic inflammation enhances the 
production of inflammatory cytokines, which might 
increase the development and growth of cancer.42 In 
urologic cancers, chronic inflammation promotes tumor 
evasion and progression.43-45 Second, SLE per se decreases 
immune-cell function, which results in dysregulation of 
the immune system. Generally, a healthy immune system 
removes aberrantly replicating cells to prevent malignancies, 
whereas this process may be impaired in SLE patients.46 
In particular, the use of immunosuppressive agents has an 
influence on the risk of cancer in SLE patients.47 Several 
case series suggested that immunosuppressive agents 
increased the risk of bladder cancer in patients with SLE.48-
50 Bernasky et al reported that immunosuppressive therapy 
in patients with SLE increased the bladder cancer risk 
by 25%.51 SLE patients who receive immunosuppressive 
therapy may be exposed to harmful side effects and 
immune impairment, which may lead to cell damage and 
promote tumor genesis.32 Immunosuppressants damage 
cells directly, and the immune-compromised state impairs 
the body’s ability to repair destroyed or damaged cells and 
cellular DNA.52
This study has several limitations. First, there was high 
heterogeneity in the rates of kidney cancer and bladder 
cancer across the studies. This might hinder accurate 
estimation of the risks associated with SLE; however, we 
conducted subgroup analyses to minimize the confounding 
factors that contributed to heterogeneity. Second, we 
could not evaluate the cumulative effects of exposure to 
immune suppressants and disease activity because of lack 
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of studies that included those data. Third, we could not 
assess confounding variables, such as smoking, alcohol 
history, and chronic diseases.
Despite the limitations, our results strongly indicate 
that SLE increases the risk of bladder cancer, but not those 
of prostate cancer and kidney cancer. Our results might 
be helpful to guide physicians that care for patients with 
SLE and urologic cancers. Our results also add to the body 
of evidence that can be used to develop better strategies 
to screen for and follow-up on incident urologic cancers 
in SLE patients. More well-designed prospective studies 
and more experimental data are needed to elucidate the 
underlying mechanisms of the associations between SLE 
and urologic cancers.
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